RecruitingMajor Depressive Disorder
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Eligible age
18–74 yrs
Accepts
All genders
Locations
21 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Sponsor: Xenon Pharmaceuticals Inc.
Where it's recruiting
Arizona
Phoenix
Arkansas
Little Rock · Rogers
California
Glendale · Huntington Beach · Irvine · Los Angeles …
Colorado
Denver
Connecticut
Cromwell
Florida
Coral Springs · Hialeah · Jacksonville · Lakeland …
Georgia
Atlanta · Decatur · Marietta · Savannah
Idaho
Boise
Illinois
Chicago
Massachusetts
Boston · Springfield
Missouri
St Louis
Nevada
Las Vegas
Source: ClinicalTrials.gov · NCT06775379 · last updated 2026-08-03